FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136757008> ?p ?o ?g. }

• W3136757008 abstract "This is a updated version of our Cochrane Review published in Issue 6, 2012. Sexually-transmitted infections (STIs) continue to rise worldwide, imposing an enormous morbidity and mortality burden. Effective prevention strategies, including microbicides, are needed to achieve the goals of the World Heath Organization (WHO) global strategy for the prevention and control of these infections.To determine the effectiveness and safety of topical microbicides for preventing acquisition of STIs, including HIV.We undertook a comprehensive search of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, CLIB, Web of Science, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, and reference lists of relevant articles up to August 2020. In addition, we contacted relevant organisations and experts.We included randomised controlled trials of vaginal microbicides compared to placebo (except for nonoxynol-9 because it is covered in related Cochrane Reviews). Eligible participants were sexually-active non-pregnant, WSM and MSM, who had no laboratory confirmed STIs.Two review authors independently screened and selected studies, extracted data, and assessed risks of bias in duplicate, resolving differences by consensus. We conducted a fixed-effect meta-analysis, stratified by type of microbicide, and assessed the certainty of the evidence using the GRADE approach.We included eight trials from the earlier version of the review and four new trials, i.e. a total of 12 trials with 32,464 participants (all WSM). We did not find any eligible study that enrolled MSM or reported fungal STI as an outcome. We have no study awaiting assessment. All 12 trials were conducted in sub-Saharan Africa, with one having a study site in the USA, and another having a site in India. Vaginal microbicides tested were BufferGel and PRO 2000 (1 trial, 3101 women), Carraguard (1 trial, 6202 women), cellulose sulphate (2 trials, 3069 women), dapivirine (2 trials, 4588 women), PRO 2000 (1 trial, 9385 women), C31G (SAVVY) (2 trials, 4295 women), and tenofovir (3 trials, 4958 women). All microbicides were compared to placebo and all trials had low risk of bias. Dapivirine probably reduces the risk of acquiring HIV infection: risk ratio (RR) 0.71, (95% confidence interval (CI) 0.57 to 0.89, I2 = 0%, 2 trials, 4588 women; moderate-certainty evidence). The other microbicides may result in little to no difference in the risk of acquiring HIV (low-certainty evidence); including tenofovir (RR 0.83, 95% CI 0.68 to 1.02, cellulose sulphate (RR 1.20, 95% CI 0.74 to 1.95, BufferGel (RR 1.05, 95% CI 0.73 to 1.52), Carraguard (RR 0.89, 95% CI 0.71 to 1.11), PRO 2000 (RR 0.93, 95% CI 0.77 to 1.14), and SAVVY (RR 1.38, 95% CI 0.79 to 2.41). Existing evidence suggests that cellulose sulphate (RR 0.99, 95% CI 0.37 to 2.62, 1 trial, 1425 women), and PRO 2000 (RR 0.95, 95% CI 0.73 to 1.23) may result in little to no difference in the risk of getting herpes simplex virus type 2 infection (low-certainty evidence). Two studies reported data on tenofovir's effect on this virus. One suggested that tenofovir may reduce the risk (RR 0.55, 95% CI 0.36 to 0.82; 224 participants) while the other did not find evidence of an effect (RR 0.94, 95% CI 0.85 to 1.03; 1003 participants). We have not reported the pooled result because of substantial heterogeneity of effect between the two studies (l2 = 85%). The evidence also suggests that dapivirine (RR 1.70, 95% CI 0.63 to 4.59), tenofovir (RR 1.27, 95% CI 0.58 to 2.78), cellulose sulphate (RR 0.69, 95% CI 0.26 to 1.81), and (Carraguard (RR 1.07, 95% CI 0.75 to 1.52) may have little or no effect on the risk of acquiring syphilis (low-certainty evidence). In addition, dapivirine (RR 0.97, 95% CI 0.89 to 1.07), tenofovir (RR 0.90, 95% CI 0.71 to 1.13), cellulose sulphate (RR 0.70, 95% CI 0.49 to 0.99), BufferGel (RR 0.97, 95% CI 0.65 to 1.45), Carraguard (RR 0.96, 95% CI 0.83 to 1.12), and PRO 2000 (RR 1.01, 95% CI 0.84 to 1.22) may result in little to no difference in the risk of acquiring chlamydia infection (low-certainty evidence). The evidence also suggests that current topical microbicides may not have an effect on the risk of acquiring gonorrhoea, condyloma acuminatum, trichomoniasis, or human papillomavirus infection (low-certainty evidence). Microbicide use in the 12 trials, compared to placebo, did not lead to any difference in adverse event rates. No study reported on acceptability of the intervention. AUTHORS' CONCLUSIONS: Current evidence shows that vaginal dapivirine microbicide probably reduces HIV acquisition in women who have sex with men. Other types of vaginal microbicides have not shown evidence of an effect on acquisition of STIs, including HIV. Further research should continue on the development and testing of new microbicides." @default.
• W3136757008 created "2021-03-29" @default.
• W3136757008 creator A5006222253 @default.
• W3136757008 creator A5019047474 @default.
• W3136757008 creator A5020155209 @default.
• W3136757008 creator A5058471224 @default.
• W3136757008 date "2021-03-13" @default.
• W3136757008 modified "2023-09-23" @default.
• W3136757008 title "Topical microbicides for preventing sexually transmitted infections" @default.
• W3136757008 cites W1495630488 @default.
• W3136757008 cites W1580890133 @default.
• W3136757008 cites W1725500992 @default.
• W3136757008 cites W1784833380 @default.
• W3136757008 cites W1941748532 @default.
• W3136757008 cites W1945557331 @default.
• W3136757008 cites W1968982315 @default.
• W3136757008 cites W1970878337 @default.
• W3136757008 cites W1972580130 @default.
• W3136757008 cites W1981594691 @default.
• W3136757008 cites W1981740153 @default.
• W3136757008 cites W1983913424 @default.
• W3136757008 cites W1986445745 @default.
• W3136757008 cites W1991703470 @default.
• W3136757008 cites W1994566416 @default.
• W3136757008 cites W1996438473 @default.
• W3136757008 cites W2000044867 @default.
• W3136757008 cites W2005512787 @default.
• W3136757008 cites W2009819282 @default.
• W3136757008 cites W2010256060 @default.
• W3136757008 cites W2013817765 @default.
• W3136757008 cites W2013979658 @default.
• W3136757008 cites W2017133346 @default.
• W3136757008 cites W2022056287 @default.
• W3136757008 cites W2025396127 @default.
• W3136757008 cites W2028046707 @default.
• W3136757008 cites W2029160886 @default.
• W3136757008 cites W2037432907 @default.
• W3136757008 cites W2039418122 @default.
• W3136757008 cites W2042613475 @default.
• W3136757008 cites W2044369525 @default.
• W3136757008 cites W2056107172 @default.
• W3136757008 cites W2058336946 @default.
• W3136757008 cites W2063457754 @default.
• W3136757008 cites W2067896431 @default.
• W3136757008 cites W2071807092 @default.
• W3136757008 cites W2076358171 @default.
• W3136757008 cites W2079439636 @default.
• W3136757008 cites W2083923088 @default.
• W3136757008 cites W2085304018 @default.
• W3136757008 cites W2100223549 @default.
• W3136757008 cites W2101299963 @default.
• W3136757008 cites W2101858999 @default.
• W3136757008 cites W2104675861 @default.
• W3136757008 cites W2107021177 @default.
• W3136757008 cites W2110483056 @default.
• W3136757008 cites W2114527378 @default.
• W3136757008 cites W2122134459 @default.
• W3136757008 cites W2135400982 @default.
• W3136757008 cites W2138665933 @default.
• W3136757008 cites W2139088256 @default.
• W3136757008 cites W2144198686 @default.
• W3136757008 cites W2145364824 @default.
• W3136757008 cites W2145471187 @default.
• W3136757008 cites W2146634980 @default.
• W3136757008 cites W2147675843 @default.
• W3136757008 cites W2147778918 @default.
• W3136757008 cites W2157823046 @default.
• W3136757008 cites W2160010002 @default.
• W3136757008 cites W2160780945 @default.
• W3136757008 cites W2167246391 @default.
• W3136757008 cites W2168445160 @default.
• W3136757008 cites W2169563864 @default.
• W3136757008 cites W2192116738 @default.
• W3136757008 cites W2290010664 @default.
• W3136757008 cites W2319075216 @default.
• W3136757008 cites W2345091379 @default.
• W3136757008 cites W2558446330 @default.
• W3136757008 cites W2567362164 @default.
• W3136757008 cites W2588681363 @default.
• W3136757008 cites W2609231153 @default.
• W3136757008 cites W2615437891 @default.
• W3136757008 cites W2898138831 @default.
• W3136757008 cites W2916841405 @default.
• W3136757008 cites W3017301742 @default.
• W3136757008 cites W4250855096 @default.
• W3136757008 cites W53189097 @default.
• W3136757008 cites W98747263 @default.
• W3136757008 doi "https://doi.org/10.1002/14651858.cd007961.pub3" @default.
• W3136757008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8092571" @default.
• W3136757008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33719075" @default.
• W3136757008 hasPublicationYear "2021" @default.
• W3136757008 type Work @default.
• W3136757008 sameAs 3136757008 @default.
• W3136757008 citedByCount "6" @default.
• W3136757008 countsByYear W31367570082021 @default.
• W3136757008 countsByYear W31367570082022 @default.
• W3136757008 countsByYear W31367570082023 @default.
• W3136757008 crossrefType "journal-article" @default.
• W3136757008 hasAuthorship W3136757008A5006222253 @default.
• W3136757008 hasAuthorship W3136757008A5019047474 @default.

• next